OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer

Molecular Oncology

Volumn 8, Issue 7, 2014, Pages 1196-1207

  Sänger, Nicole ^a   Ruckhäberle, Eugen ^b   Bianchini, Giampaolo ^c   Heinrich, Tomas ^a   Milde Langosch, Karin ^d   Müller, Volkmar ^d   Rody, Achim ^e   Solomayer, Erich Franz ^f   Fehm, Tanja ^b   Holtrich, Uwe ^a   Becker, Sven ^a   Karn, Thomas ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

Breast cancer; Cohort bias; Dataset pooling; Gene expression profiling; Osteoprotegerin; Progesteron receptor; RANK; RANKL

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROGESTERONE RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR MARKER; ESTROGEN RECEPTOR; TRANSCRIPTOME;

ADULT; ARTICLE; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER PROGNOSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMAN; BREAST; BREAST NEOPLASMS; GENETICS; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; PROGNOSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84908548743     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.04.003     Document Type: Article

References (55)

1. Azim H.A., Michiels S., Bedard P.L., Singhal S.K., Criscitiello C., Ignatiadis M., Haibe-Kains B., Piccart M.J., Sotiriou C., Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin. Cancer Res. 2012, 18:1341-1351.
2. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K.K., Carter S.L., Frederick A.M., Lawrence M.S., Sivachenko A.Y., Sougnez C., Zou L., Cortes M.L., Fernandez-Lopez J.C., Peng S., Ardlie K.G., Auclair D., et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
3. Bauer K., Parise C., Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 2010, 10:228.
4. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J.Bone Miner. Res. 2001, 16:348-360.
5. Body J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J., Harousseau J., Lipton A., Mariette X., Williams C.D., Nakanishi A., Holloway D., Martin S.W., Dunstan C.R., Bekker P.J. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97(3 Suppl):887-892.
6. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat. Rev. Cancer 2013, 13:385-396.
7. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
8. Coleman R., Gnant M., Morgan G., Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J.Natl. Cancer Inst. 2012, 104:1059-1067.
9. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., Dowsett M., Ingle J., Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
10. Dougall W.C. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin. Cancer Res. 2012, 18:326-335.
11. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., Cuzick J., Houghton J., Williams N., Mallon E., Bishop H., Ellis I., Larsimont D., Sasano H., Carder P., Cussac A.L., Knox F., Speirs V., Forbes J., Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J.Clin. Oncol. 2008, 26:1059-1065.
12. Dunnwald L.K., Rossing M.A., Li C.I. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9:R6.
13. Dupuy A., Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J.Natl. Cancer Inst. 2007, 99:147-157.
14. Ertel A. Bimodal gene expression and biomarker discovery. Cancer Inform 2010, 9:11-14.
15. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., Boyle W.J., Khokha R., Penninger J.M. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
16. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
17. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
18. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R., Pinkas J., Branstetter D., Dougall W.C. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
19. González-Suárez E. RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin. Transl Oncol. 2011, 13:222-228.
20. Grann V.R., Troxel A.B., Zojwalla N.J., Jacobson J.S., Hershman D., Neugut A.I. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005, 103:2241-2251.
21. Gyorffy B., Lánczky A., Szállási Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 2012, 19:197-208.
22. Gyorffy B., Benke Z., Lánczky A., Balázs B., Szállási Z., Timár J., Schäfer R. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res. Treat 2012, 132:1025-1034.
23. Hanker L.C., Rody A., Holtrich U., Pusztai L., Ruckhaeberle E., Liedtke C., Ahr A., Heinrich T.M., Sänger N., Becker S., Karn T. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res. Treat 2013, 137:407-416.
24. Hellwig B., Hengstler J.G., Schmidt M., Gehrmann M.C., Schormann W., Rahnenführer J. Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. BMC Bioinformatics 2010, 11:276.
25. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
26. Hugh J., Hanson J., Cheang M.C.U., Nielsen T.O., Perou C.M., Dumontet C., Reed J., Krajewska M., Treilleux I., Rupin M., Magherini E., Mackey J., Martin M., Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J.Clin. Oncol. 2009, 27:1168-1176.
27. Karn T., Metzler D., Ruckhäberle E., Hanker L., Gätje R., Solbach C., Ahr A., Schmidt M., Holtrich U., Kaufmann M., Rody A. Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res. Treat 2010, 120:567-579.
28. Karn T., Pusztai L., Holtrich U., Iwamoto T., Shiang C.Y., Schmidt M., Müller V., Solbach C., Gaetje R., Hanker L., Ahr A., Liedtke C., Ruckhäberle E., Kaufmann M., Rody A. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS ONE 2011, 6:e28403.
29. Karn T., Pusztai L., Ruckhäberle E., Liedtke C., Müller V., Schmidt M., Metzler D., Wang J., Coombes K.R., Gätje R., Hanker L., Solbach C., Ahr A., Holtrich U., Rody A., Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur. J. Cancer 2012, 48:12-23.
30. Karrila S., Lee Julian Hock Ean, Tucker-Kellogg G. A comparison of methods for data-driven cancer outlier discovery, and an application scheme to semisupervised predictive biomarker discovery. Cancer Inform 2011, 10:109-120.
31. Koboldt D.C., Fulton R.S., McLellan M.D., Schmidt H., Kalicki-Veizer J., McMichael J.F., Fulton L.L., Dooling D.J., Ding L., Mardis E.R., Wilson R.K., Ally A., Balasundaram M., Butterfield Y.S.N., Carlsen R., et al. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
32. Leek J.T., Scharpf R.B., Bravo H.C., Simcha D., Langmead B., Johnson W.E., Geman D., Baggerly K., Irizarry R.A. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 2010, 11:733-739.
33. Lipton A., Fizazi K., Stopeck A.T., Henry D.H., Brown J.E., Yardley D.A., Richardson G.E., Siena S., Maroto P., Clemens M., Bilynskyy B., Charu V., Beuzeboc P., Rader M., Viniegra M., Saad F., Ke C., Braun A., Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 2012, 48:3082-3092.
34. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. J.Clin. Oncol. 2005, 23:9067-9072. Reporting recommendations for tumor marker prognostic studies.
35. Mihály Z., Kormos M., Lánczky A., Dank M., Budczies J., Szász M.A., Gyorffy B. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res. Treat 2013, 140:219-232.
36. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U S A 2005, 102:13550-13555.
37. Minn A.J., Gupta G.P., Padua D., Bos P., Nguyen D.X., Nuyten D., Kreike B., Zhang Y., Wang Y., Ishwaran H., Foekens J.A., van de Vijver Marc, Massagué J. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. U. S. A 2007, 104:6740-6745.
38. Nakashima T., Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J.Clin. Immunol. 2009, 29:555-567.
39. Palafox M., Ferrer I., Pellegrini P., Vila S., Hernandez-Ortega S., Urruticoechea A., Climent F., Soler M.T., Muñoz P., Viñals F., Tometsko M., Branstetter D., Dougall W.C., González-Suárez E. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res. 2012, 72:2879-2888.
40. Prat A., Cheang M.C.U., Martín M., Parker J.S., Carrasco E., Caballero R., Tyldesley S., Gelmon K., Bernard P.S., Nielsen T.O., Perou C.M. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J.Clin. Oncol. 2013, 31:203-209.
41. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
42. Rody A., Karn T., Liedtke C., Pusztai L., Ruckhaeberle E., Hanker L., Gaetje R., Solbach C., Ahr A., Metzler D., Schmidt M., Müller V., Holtrich U., Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011, 13:R97.
43. Santini D., Perrone G., Roato I., Godio L., Pantano F., Grasso D., Russo A., Vincenzi B., Fratto M.E., Sabbatini R., Della Pepa C., Porta C., Del Conte A., Schiavon G., Berruti A., et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J.Cell. Physiol. 2011, 226:780-784.
44. Schmidt M., Böhm D., Törne C., von Steiner E., Puhl A., Pilch H., Lehr H.-A., Hengstler J.G., Kölbl H., Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68:5405-5413.
45. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., Hanada R., Joshi P.A., Aliprantis A., Glimcher L., Pasparakis M., Khokha R., Ormandy C.J., Widschwendter M., Schett G., Penninger J.M. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
46. Shibata D. Cancer. Heterogeneity and tumor history. Science 2012, 336:304-305.
47. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J.Natl. Cancer Inst. 2009, 101:1446-1452.
48. Stopeck A.T., Lipton A., Body J.-J., Steger G.G., Tonkin K., de Boer Richard H., Lichinitser M., Fujiwara Y., Yardley D.A., Viniegra M., Fan M., Jiang Q., Dansey R., Jun S., Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J.Clin. Oncol. 2010, 28:5132-5139.
49. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J.Q., Hoffman R.M., Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553.
50. Tanos T., Sflomos G., Echeverria P.C., Ayyanan A., Gutierrez M., Delaloye J.-F., Raffoul W., Fiche M., Dougall W., Schneider P., Yalcin-Ozuysal O., Brisken C. Progesterone/RANKL is a major regulatory axis in the human breast. Sci. Transl Med. 2013, 5:182ra55.
51. Thomas Lumley rmeta: Meta-Analysis 2012, http://CRAN.R-project.org/package=rmeta.
52. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., Raffoul J., Neven P., Orosz Z., Braye S., Ohlschlegel C., Thürlimann B., Gelber R.D., Castiglione-Gertsch M., Price K.N., Goldhirsch A., Gusterson B.A., Coates A.S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J.Clin. Oncol. 2007, 25:3846-3852.
53. Wang J., Wen S., Symmans W.F., Pusztai L., Coombes K.R. The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 2009, 7:199-216.
54. Wang Y., Klijn Jan G.M., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder, Marion E., Yu J., Jatkoe T., Berns Els M.J.J., Atkins D., Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
55. Wood C.E., Branstetter D., Jacob A.P., Cline J.M., Register T.C., Rohrbach K., Huang L.-Y., Borgerink H., Dougall W.C. Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res. 2013, 15:R62.